433 related articles for article (PubMed ID: 18723515)
1. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.
Nawaratne V; Leach K; Felder CC; Sexton PM; Christopoulos A
J Biol Chem; 2010 Jun; 285(25):19012-21. PubMed ID: 20406819
[TBL] [Abstract][Full Text] [Related]
3. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.
Gregory KJ; Hall NE; Tobin AB; Sexton PM; Christopoulos A
J Biol Chem; 2010 Mar; 285(10):7459-74. PubMed ID: 20051519
[TBL] [Abstract][Full Text] [Related]
4. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.
Keov P; López L; Devine SM; Valant C; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
J Biol Chem; 2014 Aug; 289(34):23817-37. PubMed ID: 25006252
[TBL] [Abstract][Full Text] [Related]
6. The pharmacology of McN-A-343.
Mitchelson FJ
Pharmacol Ther; 2012 Aug; 135(2):216-45. PubMed ID: 22643681
[TBL] [Abstract][Full Text] [Related]
7. Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative.
Suga H; Ehlert FJ
Biochem Pharmacol; 2010 Apr; 79(7):1025-35. PubMed ID: 19913516
[TBL] [Abstract][Full Text] [Related]
8. Utility of an "Allosteric Site-Impaired" M
Moo EV; Sexton PM; Christopoulos A; Valant C
Mol Pharmacol; 2018 Nov; 94(5):1298-1309. PubMed ID: 30213802
[TBL] [Abstract][Full Text] [Related]
9. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
[TBL] [Abstract][Full Text] [Related]
10. Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard.
Figueroa KW; Suga H; Ehlert FJ
Br J Pharmacol; 2010 Jul; 160(6):1534-49. PubMed ID: 20590642
[TBL] [Abstract][Full Text] [Related]
11. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
Valant C; Felder CC; Sexton PM; Christopoulos A
Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
[TBL] [Abstract][Full Text] [Related]
12. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
13. Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies.
Christopoulos A; Grant MK; El-Fakahany EE
J Pharmacol Toxicol Methods; 2000; 43(1):55-67. PubMed ID: 11091130
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
[TBL] [Abstract][Full Text] [Related]
15. Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.
Suga H; Sawyer GW; Ehlert FJ
Mol Pharmacol; 2010 Oct; 78(4):745-55. PubMed ID: 20643905
[TBL] [Abstract][Full Text] [Related]
16. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
17. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
Valant C; Sexton PM; Christopoulos A
Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
[TBL] [Abstract][Full Text] [Related]
18. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
[TBL] [Abstract][Full Text] [Related]
19. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
Feng Z; Hu G; Ma S; Xie XQ
AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors.
Christopoulos A; Mitchelson F
Eur J Pharmacol; 1997 Nov; 339(2-3):153-6. PubMed ID: 9473129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
